parkinsonsnewstoday.com/new...
Mesdopetam is designed to block a dopamine receptor protein called D3 receptor, whose levels are increased in motor-related brain regions with prolonged levodopa treatment and associated dyskinesia.
In earlier Phase 1b (NCT03531060) and Phase 2a (NCT03368170) trials, the investigational therapy was shown to increase daily “on time” — that is, the time when symptoms are well-controlled, without dyskinesia.
C/L induced dyskinesia - severe wrist pain 
Graph showing levodopa levels during the day: on/off and dyskinesia
Phase 3 Positive Topline Results for Tavapadon 
Anyone participating in the Buntanetap Phase 3 trial?
